Investigational drug · Phase 3
Setidegrasib
Also called: ASP3082
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "Setidegrasib"
First trial start
2026
Feb 17, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Setidegrasib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pancreatic Cancer
- Metastatic Pancreatic Cancer
- Metastatic Pancreatic Adenocarcinoma
- Non-small Cell Lung Cancer (NSCLC)
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Setidegrasib" as an intervention, largest first.
Astellas Pharma IncAstellas (ALPMY)
NCT05382559 · 681 participants (planned) · Start Jun 8, 2022 · Primary completion Dec 31, 2028
Drug: Setidegrasib; Cetuximab and 12 more · For: Solid Tumor
Sites: Duarte, California; Santa Monica, California; Denver, Colorado · 68 sites in all
- A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic CancerPivotal-lookingRecruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT07409272 · 614 participants (planned) · Start Feb 17, 2026 · Primary completion Aug 31, 2029
Drug: Setidegrasib; Oxaliplatin and 5 more · For: Pancreatic Cancer; Metastatic Pancreatic Cancer; Metastatic Pancreatic Adenocarcinoma
Sites: Gilbert, Arizona; Tucson, Arizona; Fort Smith, Arkansas · 104 sites in all
- A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D MutationPivotal-lookingRecruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT07566052 · 356 participants (planned) · Start Aug 19, 2026 · Primary completion Jun 30, 2030
Drug: Setidegrasib; Docetaxel · For: Non-small Cell Lung Cancer (NSCLC)
Sites: Glendale, California; Los Angeles, California; San Francisco, California · 30 sites in all
- A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy AdultsActive, not recruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT07395024 · 54 participants · Start Feb 3, 2026 · Primary completion May 2, 2027
Drug: Setidegrasib; Fluconazole and 2 more · For: Healthy Volunteer
Sites: Baltimore, Maryland
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT07773129 · 8 participants · Start Aug 28, 2026 · Primary completion Oct 20, 2026
Drug: 14C-labeled ASP3082 · For: Healthy Volunteer
Sites: Madison, Wisconsin
Newest research
PubMed records naming it or its code names, newest first.
- KRAS in pancreatic cancer: from molecular biology to transformative therapeutics.
Abdelhakeem A, Ganatra N, Gul K, et al. · J Hematol Oncol 2026
- Oncogenic RAS as an adaptive signaling ecosystem: context-dependent vulnerabilities and resistance-informed therapeutic design.
Hamidi AA, Moaven O, Mahmoudian RA, et al. · Exp Hematol Oncol 2026
- Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers.
Chatterjee S, Arya S, Sharma N, et al. · Med Oncol 2026
- The ongoing first-line treatment race for metastatic pancreatic ductal adenocarcinomas: will a tough disease lose its horror?
Dempke WCM, Sippel C, Fenchel K, et al. · Future Oncol 2026
- Progress and challenges in the design and development of selective KRAS G12D-targeted drug discovery: inhibitors, degraders and emerging therapeutic strategies.
Jeon E, Song J, Sim T · Future Med Chem 2026
- Contemporary Landscape of Active Clinical Trials in Pancreatic Ductal Adenocarcinoma: A ClinicalTrials.gov-Based Narrative Review with a Scoping Approach.
Rado¡ L, Matulik Čubranik S, Golčik M, et al. · Pharmaceuticals (Basel) 2026
Also in development for Pancreatic Cancer
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- CadonilimabAK104Phase 331 trials
Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- AK117Phase 314 trials
Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- JAB-21822Glecirasib Citrate, KRAS G12C inhibitorPhase 310 trials
Allist Pharmaceuticals, Inc. · Non-small Cell Lung Cancer, KRAS P.G12C, Solid Tumor
- GEMPhase 35 trials
Shenzhen Majory Biotechnology Co., Ltd. · Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Cancer, Recurrent or Metastatic Cervical Cancer
- HRS-7058Phase 35 trials
Shandong Suncadia Medicine Co., Ltd. · KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment, Solid Tumors, Pancreatic Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Astellas.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.